Expert Opinion on Therapeutic Targets

Papers
(The H4-Index of Expert Opinion on Therapeutic Targets is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Decoding the expression pattern of MUC3A in gastric adenocarcinoma: unveiling the key to successful immunotherapy72
Potential role of indole-3-propionic acid in tuberculosis: current perspectives and future prospects57
CDK7 as a New therapeutic target in pancreatic and lung cancer: current evidence and future perspectives46
The clinical and immunological features of alopecia areata following SARS-CoV-2 infection or COVID-19 vaccines44
Mitochondrial permeability transition pore: a snapshot of a therapeutic target44
IL-36: a therapeutic target for ulcerative colitis?43
Interleukin-18 in cancer immunology and immunotherapy42
Targeting transcription in neuroblastoma: focus on the core regulatory circuit39
Calcium channelopathies in neurodegenerative disorder: an untold story of RyR and SERCA38
Glycoproteins and longevity: an interview with Professor Gordan Lauc36
Molecular basis for targeting TBK1 in CAR-T cell therapies for cancer35
Pleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement32
The membrane receptor CD44: roles in neurodegenerative diseases31
The sigma–1 receptor: a mechanistically–informed therapeutic target for antidepressants28
The potential of multimolecular G-quadruplex structures for targeted treatment of Amyotrophic Lateral Sclerosis27
Current challenges in the discovery of treatments against Mayaro fever26
Blocking glycan production by targeting GALNT7 for prostate cancer therapy24
Identification of target sites in the VHR (DUSP3) enzyme unlocking potential avenues for future sepsis treatment24
MDA-9/Syntenin as a therapeutic cancer metastasis target: current molecular and preclinical understanding23
KRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications22
Antibacterial carbonic anhydrase inhibitors targeting Vibrio cholerae enzymes22
Kallikrein-related peptidases: mechanistic understanding for potential therapeutic targeting in cancer22
The challenges and potential of microRNA-based therapy for patients with liver failure syndromes and hepatocellular carcinoma22
Lipid-laden foam cells in the pathology of atherosclerosis: shedding light on new therapeutic targets22
Novel signatures of prostate cancer progression and therapeutic resistance22
0.22260904312134